Quick filters:
Open Data
Open Code
Pre-registered
Funding Declared
COI Declared
Open Access
Clear Filters
R-Spondin1 protects gastric stem cells and mitigates gastric GVHD in allogeneic hematopoietic stem cell transplantation.
Hayase E; Ara T; Saito Y; Takahashi S; Yoshioka K; Ohigashi H; Ogasawara R; Yokoyama E; Yamakawa T; Ebata K; Hasegawa Y; Tomizuka K; Teshima T.
Blood Adv
(Unknown)
Published: 2024
Intensive care risk and long-term outcomes in pediatric allogeneic hematopoietic cell transplant recipients.
Zinter MS; Brazauskas R; Strom J; Chen S; Bo-Subait S; Sharma A; Beitinjaneh A; Dimitrova D; Guilcher G; Preussler J; Myers K; Bhatt NS; Ringden O; Hematti P; Hayashi RJ; Patel S; De Oliveira SN; Rotz S; Badawy SM; Nishihori T; Buchbinder D; Hamilton B; Savani B; Schoemans H; Sorror M; Winestone L; Duncan C; Phelan R; Dvorak CC.
Blood Adv
(Unknown)
Published: 2024
Prognostic risk signature in patients with acute myeloid leukemia treated with hypomethylating agents and venetoclax.
Bataller A; Bazinet A; DiNardo CD; Maiti A; Borthakur G; Daver NG; Short NJ; Jabbour EJ; Issa GC; Pemmaraju N; Yilmaz M; Montalban-Bravo G; Takahashi K; Loghavi S; Garcia-Manero G; Ravandi F; Kantarjian HM; Kadia TM.
Blood Adv
(Unknown)
Published: 2024
MRD-driven treatment with venetoclax-R2 in mantle cell lymphoma: the Nordic Lymphoma Group MCL7 VALERIA trial.
Jerkeman M; Kolstad A; Hutchings M; Pasanen A; Meriranta L; Niemann CU; Kragh Jørgensen RR; El-Galaly TC; Riise J; Leppä S; Christensen JH; Sonnevi K; Pedersen LB; Wader KF; Glimelius I.
Blood Adv
(Unknown)
Published: 2024
Bendamustine lymphodepletion before axicabtagene ciloleucel is safe and associates with reduced inflammatory cytokines.
Ghilardi G; Paruzzo L; Svoboda J; Chong EA; Shestov AA; Chen L; Cohen IJ; Gabrielli G; Nasta SD; Porazzi P; Landsburg DJ; Gerson JN; Carter J; Barta SK; Yelton R; Pajarillo R; Patel V; White G; Ballard HJ; Weber E; Napier E; Chong ER; Fraietta JA; Garfall AL; Porter DL; Milone MC; O'Connor R; Schuster SJ; Ruella M.
Blood Adv
(Unknown)
Published: 2024
Heightened TLR7 signaling primes BCR-activated B cells in chronic graft-versus-host disease for effector functions.
Bracken SJ; Suthers AN; DiCioccio RA; Su H; Anand S; Poe JC; Jia W; Visentin J; Basher F; Jordan CZ; McManigle WC; Li Z; Hakim FT; Pavletic SZ; Bhuiya NS; Ho VT; Horwitz ME; Chao NJ; Sarantopoulos S.
Blood Adv
(Unknown)
Published: 2024
A phase 2 study of the PI3Kδ inhibitor parsaclisib in relapsed and refractory marginal zone lymphoma (CITADEL-204).
Phillips TJ; Avigdor A; Gurion R; Patti C; Corradini P; Tani M; Mehta A; Lossos IS; Zinzani PL; Thieblemont C; Jurczak W; Zheng F; Rappold E; Zhao W; Jiang P; Johnson P.
Blood Adv
(Unknown)
Published: 2024
A descriptive analysis of fatal outcomes in immune thrombotic thrombocytopenic purpura in the USTMA TTP Registry.
Abou-Ismail MY; Zhang C; Presson AP; Chaturvedi S; Antun AG; Farland AM; Woods R; Metjian A; Park YA; de Ridder G; Gibson B; Kasthuri RS; Liles DK; Akwaa F; Clover T; Baumann Kreuziger L; Sridharan M; Go RS; McCrae KR; Upreti HV; Gangaraju R; Kocher NK; Zheng XL; Raval JS; Masias C; Cataland SR; Johnson AD; Davis E; Evans MD; Mazepa M; Lim MY.
Blood Adv
(Unknown)
Published: 2024
Cord blood transplantation for adult mature lymphoid neoplasms in Europe and Japan.
Watanabe M; Kanda J; Volt F; Ruggeri A; Suzuki R; Rafii H; Kimura F; Cappelli B; Kondo E; Scigliuolo GM; Takahashi S; Kenzey C; Rivera-Franco MM; Okamoto S; Rocha V; Chevallier P; Sanz J; Fürst S; Cornelissen J; Milpied N; Uchida N; Sugio Y; Kimura T; Ichinohe T; Fukuda T; Mohty M; Peffault de Latour R; Atsuta Y; Gluckman E.
Blood Adv
(Unknown)
Published: 2024
Systematic evaluation of donor-KIR/recipient-HLA interactions in HLA-matched hematopoietic cell transplantation for AML.
Fein JA; Shouval R; Krieger E; Spellman SR; Wang T; Baldauf H; Fleischhauer K; Kröger N; Horowitz M; Maiers M; Miller JS; Mohty M; Nagler A; Weisdorf D; Malmberg KJ; Toor AA; Schetelig J; Romee R; Koreth J.
Blood Adv
(Unknown)
Published: 2024
Phase 1b trial of tagraxofusp in combination with azacitidine with or without venetoclax in acute myeloid leukemia.
Lane AA; Garcia JS; Raulston EG; Garzon JL; Galinsky I; Baxter EW; Leonard R; DeAngelo DJ; Luskin MR; Reilly CR; Stahl M; Stone RM; Vedula RS; Wadleigh MM; Winer ES; Mughal T; Brooks C; Gupta IV; Stevenson KE; Neuberg DS; Ren S; Keating J; Konopleva M; Stein A; Pemmaraju N.
Blood Adv
(Unknown)
Published: 2024
Three years of maintenance with VRD in multiple myeloma: results of total therapy IIIB with a 15-year follow-up.
Al Hadidi S; Ababneh OE; Schinke CD; Thanendrarajan S; Bailey C; Smith R; Panozzo S; Alapat D; Cottler-Fox M; Tricot G; Shaughnessy JD; Zhan F; Sawyer J; Barlogie B; Zangari M; van Rhee F.
Blood Adv
(Unknown)
Published: 2024
Daratumumab for patients with myeloma with early or late relapse after initial therapy: subgroup analysis of CASTOR and…
Spencer A; Moreau P; Mateos MV; Goldschmidt H; Suzuki K; Levin MD; Sonneveld P; Orlowski RZ; Yoon SS; Usmani SZ; Weisel K; Reece D; Ahmadi T; Pei H; Mayo WG; Gai X; Carey J; Bartlett JB; Carson R; Dimopoulos MA.
Blood Adv
(Unknown)
Published: 2024
Functional relevance of circRNA aberrant expression in pediatric acute leukemia with KMT2A::AFF1 fusion.
Tretti Parenzan C; Molin AD; Longo G; Gaffo E; Buratin A; Cani A; Boldrin E; Serafin V; Guglielmelli P; Vannucchi AM; Cazzaniga G; Biondi A; Locatelli F; Meyer LH; Buldini B; Te Kronnie G; Bresolin S; Bortoluzzi S.
Blood Adv
(Unknown)
Published: 2024
Increased age-associated B cells in patients with acquired aplastic anemia correlate with IFN-γ.
Solomou EE; Kattamis A; Symeonidis A; Sirinian C; Salamaliki C; Tzanoudaki M; Diamantopoulos P; Plakoula E; Palasopoulou M; Giannakoulas N; Kontandreopoulou CN; Kollia P; Viniou NA; Galanopoulos A; Liossis SN; Vassilopoulos G.
Blood Adv
(Unknown)
Published: 2024
Longitudinal clinical data improve survival prediction after hematopoietic cell transplantation using machine learning.
Zhou Y; Smith J; Keerthi D; Li C; Sun Y; Mothi SS; Shyr DC; Spitzer B; Harris A; Chatterjee A; Chatterjee S; Shouval R; Naik S; Bertaina A; Boelens JJ; Triplett BM; Tang L; Sharma A.
Blood Adv
(Unknown)
Published: 2024
Oxygen gradient ektacytometry-derived biomarkers are associated with acute complications in sickle cell disease.
Rab MAE; Kanne CK; Boisson C; Bos J; van Oirschot BA; Houwing ME; Renoux C; Bartels M; Rijneveld AW; Nur E; Cnossen MH; Joly P; Nader E; Fort R; Connes P; van Wijk R; Sheehan VA; van Beers EJ.
Blood Adv
(Unknown)
Published: 2024